IVERIC bio $115.2 million stock offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $115.2 million SEC-registered offering of 13,397,500 shares of common stock, including the full exercise by the underwriters of their option to purchase 1,747,500 additional shares of common stock. IVERIC’s common stock is listed on the Nasdaq Global Select Market under the symbol “ISEE.”
Based in New York, New Jersey and Massachusetts, IVERIC is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. IVERIC is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.
The Davis Polk corporate team included partners Roshni Banker Cariello and Richard D. Truesdell Jr. and associates Jeannette Safi and Taeo I. Carse. The tax team included partner Ethan R. Goldman and associate Dov Sussman. Partner Pritesh P. Shah and associate Chelsea Renter provided intellectual property advice. All members of the Davis Polk team are based in the New York office.